Medicine and Dentistry
Patient
100%
Alectinib
43%
Progression Free Survival
37%
Anaplastic Lymphoma Kinase
37%
Lung Cancer
25%
Cells
25%
Follow up
18%
Overall Survival
18%
Neoplasm
12%
Survival Rate
12%
Malignant Neoplasm
12%
Therapeutic Procedure
12%
Adverse Event
6%
Combination Therapy
6%
Disease Exacerbation
6%
Phosphotransferase Inhibitor
6%
Drug Therapy
6%
Patient History of Chemotherapy
6%
Brain Metastasis
6%
ALK Inhibitor
6%
Analysis
6%
Nursing and Health Professions
Alectinib
43%
Progression Free Survival
37%
Anaplastic Lymphoma Kinase
37%
Lung Cancer
25%
Follow up
18%
Overall Survival
18%
Symptom
18%
Survival Rate
12%
Malignant Neoplasm
12%
Neoplasm
12%
Combination Therapy
6%
Adverse Event
6%
Disease Exacerbation
6%
Bilirubin Blood Level
6%
Phosphotransferase Inhibitor
6%
Procedures
6%
Analysis
6%
Brain Metastasis
6%
Anaplastic Lymphoma Kinase Inhibitor
6%
Patient History of Chemotherapy
6%
Pharmacology, Toxicology and Pharmaceutical Science
Alectinib
43%
Progression Free Survival
37%
Anaplastic Lymphoma Kinase
37%
Lung Cancer
25%
Overall Survival
18%
Symptom
18%
Neoplasm
12%
Survival Rate
12%
Malignant Neoplasm
12%
Adverse Event
6%
Disease Exacerbation
6%
Patient History of Chemotherapy
6%
Phosphotransferase Inhibitor
6%
Anaplastic Lymphoma Kinase Inhibitor
6%
Brain Metastasis
6%
Biochemistry, Genetics and Molecular Biology
Anaplastic Lymphoma Kinase
43%
Progression Free Survival
37%
Overall Survival
18%
Survival Rate
12%
Kinase
6%
Mutation
6%
Bilirubin Blood Level
6%
Neuroscience
Anaplastic Lymphoma Kinase
43%
Kinase
6%
Chemotherapy
6%
Metastasis
6%
Brain
6%